Like most of its peers in the biopharma sector, Genentech has been working on AI-powered technologies for drug discovery and development, coming up with a proprietary set of algorithms and other ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

FDA approval for the drug seems likely, although investors should be wary that on average only ... Cas9 gene editing to be ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

The study provides a valuable showcase of a workflow to perform large-scale characterization of drug mechanisms of action using proteomics in which on-target and off-targets of 166 compounds using ...

US endocrinologists are favoring antithyroid drugs over radioactive iodine in initial Graves’ disease treatment, and new ...

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

The Company announced the appointment of new members to its Board of Directors to help guide its next phase of growth and innovation, including ...

An ad-hoc analysis found a higher rate of severe and life-threatening infections in patients with RET-mutant lung cancer ...